SCN5A and heart failure: Furthermore, an SGLT2 inhibitor has been demonstrated to decrease the INa‐L in cardiomyocytes from mice with heart failure, as well as in cells expressing the SCN5A–R1623Q or SCN5A–ΔKPQ mutations.350